Abstract
Trypsin, chymotrypsin and elastase were combined to hydrolyze scorpion Buthus marstesii Karsch powders to prepare scorpion peptides (SP). Orthogonal design experiment L16 (44) was used to optimize variables of enzymolysis temperature, time, pH and enzyme concentration. Degree of hydrolysis (DH) and inhibition rate (IR) of A549 cells were selected as analysis indicators. The optimum enzymolysis conditions were determined as follows: enzymolysis temperature 40°C, time 3h, pH 8.5 and enzyme concentration of each 2000U. The anti-tumor activity of SP was determined on a panel of representative cell lines (A549, MCF7 and EC109) using MTT assay. In vitro, SP significantly inhibited the proliferation of A549, which was more obvious than MCF-7 and EC109. Further experiments on cell apoptosis and cell cycle analysis revealed that SP induce apoptosis and arrest cell cycle progression in S phase.
Keywords: Orthogonal design experiment, enzymolysis conditions, anti-tumor activity, cell apoptosis, cell cycle analysis.
Current Signal Transduction Therapy
Title:Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Volume: 11 Issue: 1
Author(s): Fangwen Jiao, Jihui Wang, Yuhong Liu, Yan Zou, Wei Jia, Panpan Zhang, Jing Sun, Youwei Xu and Junxiang Wang
Affiliation:
Keywords: Orthogonal design experiment, enzymolysis conditions, anti-tumor activity, cell apoptosis, cell cycle analysis.
Abstract: Trypsin, chymotrypsin and elastase were combined to hydrolyze scorpion Buthus marstesii Karsch powders to prepare scorpion peptides (SP). Orthogonal design experiment L16 (44) was used to optimize variables of enzymolysis temperature, time, pH and enzyme concentration. Degree of hydrolysis (DH) and inhibition rate (IR) of A549 cells were selected as analysis indicators. The optimum enzymolysis conditions were determined as follows: enzymolysis temperature 40°C, time 3h, pH 8.5 and enzyme concentration of each 2000U. The anti-tumor activity of SP was determined on a panel of representative cell lines (A549, MCF7 and EC109) using MTT assay. In vitro, SP significantly inhibited the proliferation of A549, which was more obvious than MCF-7 and EC109. Further experiments on cell apoptosis and cell cycle analysis revealed that SP induce apoptosis and arrest cell cycle progression in S phase.
Export Options
About this article
Cite this article as:
Jiao Fangwen, Wang Jihui, Liu Yuhong, Zou Yan, Jia Wei, Zhang Panpan, Sun Jing, Xu Youwei and Wang Junxiang, Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity, Current Signal Transduction Therapy 2016; 11(1) . https://dx.doi.org/10.2174/1574362411666160517113916
DOI https://dx.doi.org/10.2174/1574362411666160517113916 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Photothermal Therapy: A New Approach to Eradicate Cancer
Current Nanoscience Strategy for the Treatment of Helicobacter pylori Infection
Current Pharmaceutical Design Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers
Current Cardiology Reviews Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Death Receptors as Targets of Cancer Therapeutics
Current Cancer Drug Targets NMR-based Drug Development and Improvement Against Malignant Melanoma – Implications for the MIA Protein Family
Current Medicinal Chemistry Difference Gel Electrophoresis: Application in Quantitative Proteomics Research
Current Proteomics Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design